Literature DB >> 1405979

Defect reconstruction and cerebrospinal fluid management in neurotologic skull base tumors with intracranial extension.

C G Jackson1, J L Netterville, M E Glasscock, C R Hampf, V N Carrasco, D S Haynes, B Strasnick, J Fisher.   

Abstract

Intracranial extension (ICE) is the spread of tumor into the subarachnoid space through dura or along cranial nerve roots. The single-stage removal of the skull base tumor with its ICE has been confounded by cerebrospinal fluid management and defect reconstruction. The purpose of this report is to review a current protocol for managing the cranial base tumor and its ICE as a unit. The ventricular shunting paper of 1987 is retracted. All tumors were managed at a single stage. Defect reconstruction was size dependent. Ninety-eight neurotologic skull base tumors with ICE were managed from 1971 to 1991. The new protocol was initiated in 1987. Results specific to this group are highlighted. For glomus tumors, cerebrospinal fluid leak rates have been dramatically reduced overall from 14.5% to 4%. The leak rates for nonglomus tumors, overall, have improved slightly. Complications are discussed. The development of this surgical approach protocol improves the functional outcome in patients of surgeons who aspire to disease "cure" rather than "control."

Entities:  

Mesh:

Year:  1992        PMID: 1405979     DOI: 10.1288/00005537-199211000-00001

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

1.  A posterolateral approach to the skull base: the petro-occipital transsigmoid approach.

Authors:  A Mazzoni; M Sanna
Journal:  Skull Base Surg       Date:  1995

2.  The Use of the Temporoparietal Fascial Flap in Preventing CSF Leak after Lateral Skull Base Surgery.

Authors:  Rusha Patel; Luke O Buchmann; Jason Hunt
Journal:  J Neurol Surg B Skull Base       Date:  2013-06-24

3.  Clinical presentation and management of jugular foramen paraganglioma.

Authors:  Sa Myung Chung; Hyun Su Kim; Jinsei Jung; Ho-Ki Lee; Won Sang Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-03-26       Impact factor: 3.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.